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clinical and procedural outcomes, in particular lower mortality, as compared with CS.
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Background: Decreased LVEF at presentation during STEMI has been established as
a predictor of morbidity and mortality. Many patients have improvement in LVEF
over time due to recovery of hibernating or stunned myocardium. Little data exists on
the clinical and angiographic predictors of improvement in LVEF after stenting.
Methods: In HORIZONS-AMI, 3,602 patients presenting with STEMI at 123 sites
were randomized to heparin + a glycoprotein IIb/IIIa inhibitor (H+GPI) vs. bivalir-
udin, and to paclitaxel-eluting stents vs. bare metal stents. Clinical follow-up was
performed for three years, including routine angiographic follow-up at 13 months in a
pre-speciﬁed substudy.
Results: Baseline and 13-month follow-up LVEF measurements were available in 656
patients, comprising the current study cohort. The median change [interquartile range]
in LVEF from baseline to 13 months was +2.4% [-5.85%, 11.80%]. During follow-up
LVEF rose or remained the same in 379 (57.8%) patients (median D +9.8% [4.30%,
16.40%]), and fell in 277 (42.2%) patients (median D -7.0% [-11.80%, -3.60%]). By
multivariable analysis, independent predictors of improvement in LVEF were female
sex (p¼0.002) and TIMI 3 ﬂow after PCI (p¼0.03), while longer lesion length
(p¼0.04), greater peak CKMB (p< 0.0001) and higher baseline LVEF (p< 0.0001)
predicted LVEF decrease (Table). Of note, use of drug-eluting vs. bare metal stents,
bivalirudin vs. H+GPI, symptom-to-balloon time, and discharge use of beta-blockers
or ACEI/ARBs were not signiﬁcant predictors of LVEF improvement.Table. Multivariable Correlates of LVEF Improvement from Baseline to
13 Months
Multivariable Correlates Odds Ratio [95% CI] (adjusted) P Value
Female sex 2.08 [1.3, 3.33] 0.002
Baseline LVEF 0.90 [0.88, 0.91] <0.0001
Peak CKMB 1.00 [1.00, 1.00] <0.0001
TIMI 3 ﬂow post-PCI 1.96 [1.06, 3.62] 0.03
Total lesion length 0.98 [0.97, 1.00] 0.04
B6 JACC Vol 64/11/Suppl B jConclusions: While LVEF improves during follow-up in more than half of patients
after primary PCI, a signiﬁcant proportion have worsening LV function over time.
Further approaches are required to improve myocardial recovery after mechanical
reperfusion therapy in STEMI.
TCT-19
Predictors of Target Vessel Revascularization after Primary Percutaneous
Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction:
Lessons from HORIZONS-AMI
Sorin Brener1, Roxana Mehran2, Konstanze Ertelt3, Philippe Genereux4, Ke Xu5,
Bernhard Witzenbichler6, Gregg W. Stone7
1New York Methodist Hospital, Brooklyn, United States, 2Icahn School of Medicine at
Mount Sinai,, New York, NY, 3Cardiovascular Research Foundation, New York City,
NY, 4Columbia University Medical Center, New York, 5Cardiovascular Research
Foundation, New York, NY, 6Charité Campus Benjamin Franklin, Berlin, Germany,
7Columbia University Medical Center and the Cardiovascular Research Foundation,
New York, United States
Background: Primary percutaneous coronary intervention (PCI) is the preferred
method of reperfusion in ST-segment elevation myocardial infarction (STEMI).
Target vessel revascularization (TVR) due to restenosis or disease progression may
compromise the beneﬁts of primary PCI. The predictors and impact of TVR after
STEMI are not well understood.
Methods: In HORIZONS AMI 3,602 patients with STEMI were randomized to
bivalirudin vs. heparin and a glycoprotein IIb/IIIa inhibitor; stents were implanted in
3,202 patients. Ischemia-driven TVR of the infarct-related artery (IRA) required
recurrent angina and/or signs of ischemia and 50% diameter restenosis, or 70%
diameter stenosis even in the absence of ischemia.
Results: TVR occurred in 219 (6.9%) patients at 1 year, 392 (12.9%) at 2 years, and 437
(14.4%) at 3 years. Repeat PCI was performed in 410 (93.0%) patients and CABG in 48
(11.4%, not mutually exclusive). TVRwas ischemia-driven in 418 patients (95.7%). TVR
was due to restenosis in 343 patients (80.2%) and disease progression in 94 (19.8%). Pa-
tients with vs. without TVR had similar rates of death (6.6% vs. 6.3%, P¼0.87), but
markedly higher rates ofMI (35.3% vs. 2.7%, P< 0.0001) and non-CABGmajor bleeding
(13.8%vs. 7.8%, P< 0.001). Of the 151MI events in the TVR group, 29 (19.2%) occurred
before (average 35 days) TVR, 13 (8.6%) occurred after (average 166 days) TVR, and the
rest (72.2%) occurred on same day asTVR.Half of theMIs beforeTVRoccurredwithin 48
hours of it, suggesting that TVRwas the result of theMI. Target lesion deﬁnite SToccurred
in 29.2% of TVR patients and in 0.4% of non-TVR group, P< 0.0001. Only one third of
them occurred beyond 1 year. Independent predictors of TVR were more extensive CAD
(HR¼1.18 per diseased vessel, P¼0.006), smaller vessel size (HR¼1.37 per mm,
P¼0.006), longer lesion length (HR¼1.01 per mm, P¼0.003), scheduled angiographic
follow-up (HR¼1.41, P¼0.001) and treatment with bare metal rather than drug-eluting
stents (HR¼1.59, P< 0.0001).
Conclusions: TVR occurs in 1 of every 7 STEMI patients within 3 years after primary
PCI, is usually due to restenosis rather than disease progression, and is strongly related
to adverse outcomes (but not death).
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Background: Myocardial perfusion is impaired in up to 40% of patients after primary
PCI (pPCI) for ST-segment elevation myocardial infarction (STEMI), which is asso-
ciated with adverse clinical outcomes. Pressure-controlled intermittent coronary sinus
occlusion (PICSO) aims to improvemicrovascular perfusion after pPCI by intermittently
increasing the pressure in the cardiac venous outﬂow tract by means of a balloon-tipped
catheter in the coronary sinus.We evaluated the safety and feasibility of adjuvant PICSO
after pPCI for STEMI, and its effects on infarct size and myocardial function.
Methods: We enrolled 30 patients after successful pPCI for anterior STEMI. PICSO
for 90 minutes was attempted, and the quantity of PICSO therapy provided throughout
the procedure was documented (mm Hg of coronary sinus pressure modulation).
Infarct size and myocardial function were assessed by cardiovascular magnetic
resonance (CMR) at 2-5 days and 4-months post-pPCI, and the results were compared
with a matched historical control group.
Results: PICSO could be initiated in 19 patients (63%). Major adverse safety events
occurred in 1 patient (3%). When PICSO could be initiated, median PICSO duration was
88.8 min (Q1–Q3: 72.0–89.6 min), and could be maintained for 90(2) minutes in 12
patients (40%). However, the quantity of PICSO therapy varied from 15 to 2735 mmHgSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM(Median: 494 mmHg (Q1-Q3: 237-828 mmHg)), which was associated with center
experience. Overall, no signiﬁcant differences in infarct size or myocardial recovery were
demonstrated between PICSO-treated and matched control patients. However, infarct size
reduction from 2-5 days to 4-months was greater for patients treated with high (>median)
PICSOquantity, compared to those treatedwith lowPICSOquantity (less than themedian)
(41.68.2% vs 21.114.1%, p¼0.02), and also compared to their matched controls
(41.68.2% vs 27.79.9%, p¼0.04).
Conclusions: PICSO is safe after pPCI for STEMI, although feasibility was limited
and depended on center experience. Administration of high PICSO quantity was
associated with enhanced infarct size reduction, suggesting a dose-effect relationship
of PICSO on myocardial recovery.
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Background: Everolimus-eluting stent (EES) is associated with a lower rate of stent
thrombosis even in the setting of ST elevation myocardial infarction (STEMI). The aim
of this study was to compare vessel responses at 3 and 6 weeks follow-up after EES or
BMS implantation using optical coherence tomography (OCT) in STEMI patient.
Methods: We recruited patients with STEMI requiring emergent PCI and who received
EES or BMS from May 2010 to February 2014. A total of 20 STEMI patients with de
novo native coronary lesions were enrolled in this study. Ten EES and 10 BMS were
implanted in STEMI patients. All patients received dual-antiplatelet therapy (clopidogrel
75 mg/day and aspirin 100 mg/day). OCT examination was performed at 3 and 6 weeks
follow-up after EESorBMS implantation.Cross-sectional area (CSA)were analyzed at 1
mm intervals. The well-apposed coverage (covered struts/ total struts  100) were
evaluated byOCT.Mean neointimal hyperplasia (NIH) thickness and%NIH ((stent area
– lumen area)/stent area  100) were also measured. The percentage of thrombi were
calculated as the (number of CSA with thrombus/total number of CSA)  100.
Results: The well-apposed coverage at 3 weeks was 87.8% with EES, 89.0% with
BMS (p¼0.78), and at 6 weeks was 96.0% with EES, 94.7% with BMS (p¼0.72). %
NIH and mean NIH thickness were signiﬁcantly lower with EES compared with BMS
at both weeks. % thrombi was signiﬁcantly lower with EES compared with BMS at 3
weeks (11.2% vs 42.6%, p< 0.01), but was similar to EES and BMS at 6 weeks (6.1%
vs 7.6%, p¼0.68). The data are shown in Table.
Conclusions: Neointimal coverage of EES was similar to BMS at 3 and 6 weeks after
implantation. However, the incidence of thrombus was signiﬁcantly lower in EES at 3
weeks, which may explain low rate of acute and subacute stent thrombosis of EES as
compared with BMS.3 weeks 6 weeks
EES BMS p EES BMS p
No. of patients (n) 5 5 5 5
Stent diameter (mm) 3.00.2 3.30.6 0.49 2.90.5 3.00.2 0.68
Stent length (mm) 40.221.2 19.05.2 <0.05 36.016.0 21.45.9 0.09
No. of stent struts (n) 366.0229.9 181.650.5 0.118 312.0159.6 284.4118.8 0.76
OCT ﬁndings
Malapposed (%) 7.66.5 12.319.8 0.63 7.35.1 0.00.0 <0.05
Well-apposed coverage
(%)
87.84.6 89.08.1 0.78 96.04.0 94.76.3 0.72
% NIH (%) 3.80.4 5.71.3 <0.05 5.01.1 15.59.4 <0.05
Mean Thickness (mm) 61.87.1 87.823.1 <0.05 66.011.6 213.9116.6 <0.05
% thrombi (%) 11.28.0 42.618.7 <0.01 6.15.1 7.65.6 0.68
No. of total CSA (n) 186 95 180 105
No. of CSA with thrombi
(n)
15 38 11 8TCT-22
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Background: Residual intrastent thrombus is readily assessed after stenting in pri-
mary percutaneous coronary intervention (PPCI), with variable level of accuracy.
Uncertain though is association of residual intrastent thrombus on prognosis and/or
left ventricular ejection fraction (LVEF). Aim of the study was to evaluate semi-
quantitatively the relation between residual intrastent thrombus as assessed by fre-
quency domain OCT (FD-OCT) after PPCI, with LVEF at discharge.
Methods: From dicember 2012 to dicember 2013, 112 consecutive patients, treated
with PPCI, were studied. Overall underwent FD-OCT after stenting. The amount of
residual intrastent thrombus was calculated as stent area minus lumen area; the % ofJACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/Acintrastent thrombus area (%ThA) was calculated as thrombus area/stent area. Patients
were divided on the basis of reduced (50%) or preserved (>50%) LVEF calculated
by echocardiography at discharge. Clinical follow-up was completed for all at 1,3,6,12
months by phone interview.
Results: After PPCI, mean LVEF in all patients was 53.639.6%. LVEF>50% was
observed in 61% (69/112) of the patients, while LVEF 50% 39% (43/112). After the
procedure, overall %ThA was 4.7  1.3. Patients with preserved LVEF >50% had
signiﬁcantly less %ThA than patients with LVEF 50% (4.31.8 vs 5.34.6;
p¼0.05). MACE were observed in 9/112 patients. Patients with MACE had higher
values of %ThA than patients without MACE (6.02.5 vs 4.51.3; p¼0.09).
Conclusions: In STEMI patients treated with PPCI, LVEF 50% seems to be asso-
ciated with more %ThA than LVEF>50%. MACE are associated with higher values of
%ThA. Residual intrastent thrombus can be a negative prognostic marker in STEMI.
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Background: The frequency, causes, and impact of myocardial infarction (MI) after
successful percutaneous coronary intervention (PCI) have not been well-studied.
Methods: ADAPT-DES was a prospective, multicenter, “all-comers” study of PCI with
drug-eluting stents (DES) in 8582 pts at 11 centers in the US andGermany.After excluding
125 pts with periprocedural MI, we investigated the etiology, frequency, and long-term
consequences of post-proceduralMI after successful and uncomplicatedDES implantation.
Results: Of 8457 pts without peri-procedural MI, post-procedural MI developed
during 2-year follow-up in 263 pts (3.1%). The median [IQR] time to post-procedural
MI was 318 [129, 503] days. Post-procedural MIs were attributable to: (1) non-target
lesion-related spontaneous MI (78 pts [29.7%]); (2) secondary (supply/demand
imbalance) or indeterminate MI (64 pts [24.3%]); (3) stent thrombosis (ST) related MI
(63 pts [24.0%]); and (4) in-stent restenosis (ISR) related MI (58 pts [22.1%]). Pts who
experienced a post-procedural MI had signiﬁcantly greater 2-year mortality than those
without MI (17.3% vs 3.4%, P< 0.001). The impact of post-procedural MI according
to etiology appears in the Figure. After adjustment for important clinical covariates,
the occurrence of post-procedural MI was associated with a 6.7-fold higher risk of
death at 2 years (95% CI 4.8 to 9.4, p< 0.001).Conclusions: Post-procedural MI within 2 years of successful DES implantation is
relatively infrequent but has numerous etiologies and is a strong independent predictor
of subsequent mortality.ute Myocardial Infarction B7
